The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 357:1260-1261 September 20, 2007 Number 12
NextNext

Prevention and Treatment of Major Blood Loss

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Mannucci, P. M.
-PubMed Citation
To the Editor: Mannucci and Levi (May 31 issue)1 review the efficacy and safety of various antifibrinolytic agents (aprotinin, tranexamic acid, and aminocaproic acid) and recombinant activated factor VII (rFVIIa) in patients undergoing cardiac and noncardiac surgery. They state that the most obvious and probably the most effective strategy to minimize the use of blood products is to improve surgical and anesthetic techniques. We would add that in patients with an acute coronary syndrome who require urgent coronary-artery bypass grafting (CABG), antiplatelet therapy with aspirin, clopidogrel, and a glycoprotein IIb/IIIa antagonist (e.g., tirofiban) should be discontinued before surgery. Timely discontinuation . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.